Results of Clinical Trials and Late Breaking News Session Submissions are now closed.
Submission deadline: Monday, 15 June 2026, 18:00 CEST.
Abstract Submission Terms & Conditions
The Euretina Session on ‘Results of Clinical Trials and Late Breaking News’ will showcase the latest innovative and breakthrough research, with findings to be presented during the Congress, which begins on 1 October 2026
Abstracts focusing on the first presentation of results of a major clinical trial are encouraged for submission.
General Terms & Conditions
– The ‘Results of Clinical Trials and Late Breaking News’ abstract submission portal will open on Tuesday, 5 May 2026 and close on Monday, 15 June – 18:00 CEST.
– Please note that you must be a Euretina Member in order to submit an abstract. If you are not a member please CLICK HERE to join.
– Presenting authors must be ophthalmologists or researchers.
– Co-authors must be ophthalmologists, researchers or other healthcare professionals who have contributed to the project.
– Each applicant may submit a maximum of 2 abstracts.
– If you choose to submit an abstract(s), only the presenting author will be contacted using their personal details to provide updates on its status, including whether it has been accepted for presentation at the Euretina Congress.
– If your abstract(s) is accepted for presentation, the presenter’s contact details (name and email address) will be sent to a third-party Audio Visual Company in order for them to contact them in relation to uploading your presentation.
Abstract Requirements
– All submitted abstracts must be submitted in the presenting author’s name.
– Financial Disclosure: Please indicate Yes/No with details where applicable. Indicate whether the presenting author or any co-author has a financial interest in the subject matter or receives funds from any mentioned companies.
– All submitted abstracts must be in English and follow the structured format below:
- Title (250 characters max)
- Purpose (100 words max)
- Setting/Venue (50 words max)
- Methods (200 words max)
- Results (200 words max)
- Conclusions (200 words max)
– Presentation titles must not include company names.
– Accepted presentations must not include company branded slides.
– Formulae should, in general, be avoided.
– When using abbreviations or acronyms for the first time, care should be taken to spell them out in full with the abbreviation in parentheses after the full word(s) the first time it appears in the text. The abbreviation should be used alone thereafter.
– The summary of results presented must be given in sufficient detail to support the conclusions. The Review Committee will only accept abstracts with final results or conclusions.
– There is an embargo on oral presentations until the first day of the annual Congress programme.
– Euretina does not take any ownership of the copyright of a presentation. However, presenters are required to sign a Non-Exclusive Transfer of Rights document at the time of the presentation upload.
– Accepted presentations will be displayed on Euretina On Demand after the Congress.
Review & Evaluation
– All submitted abstracts will be reviewed before a final selection is made.
– Specific topics that need to be covered in the Congress programme will be considered before making the final selection of accepted abstracts. The decision of the Euretina Review Committee is final.
– If your abstract is accepted for oral presentation in the Euretina Session, the presenting author will be informed of this by email in mid July 2026.
– It is not possible to reschedule the assigned time of an accepted abstract.
– If your abstract is not accepted for oral presentation, you may be offered the opportunity to present it as an e-poster.
Contact [email protected] in case of any additional questions.
Closing Date: Monday, 15 June 2026 – 18:00 CEST
Abstract Acceptance Notification: The presenting author only will be contacted about the acceptance status of your abstract in mid July 2026.